QL1209 (pertuzumab Biosimilar) Versus Reference Pertuzumab Plus Trastuzumab and Docetaxel in Neoadjuvant Treatment for HER2-positive, ER/PR-negative, Early or Locally Advanced Breast Cancer: A Multicenter, Randomized, Double-Blinded, Parallel-Controlled, Phase III Equivalence Trial